patent.fyi
Applications  /  US 2026/0356817
United States Patent Application Publication

US 2026/0356817 A1

Published
Nov 12, 2026
Filed
Aug 25, 2023
Earliest date on the face
Aug 26, 2022
Classification
C07D 403/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Nitrile on a ring carbon

What ifWhat if X1, X2, and X3 were all carbon atoms and a nitrile projected from X2?
Claim language“at least one of X1, X2, and X3 is N”

The ring retains its three attachment positions, and the terminal nitrogen of the nitrile supplies a hydrogen-bond acceptor beyond the ring perimeter. A fluorescence anisotropy assay measures the effect on binding of the MYC–MAX complex to a labeled DNA duplex.

1.2Rigid ethynylene linker

What ifWhat if Y1 were a two-carbon ethynylene linker?
Claim language“Y1 is a bond, —O—, —S—, —CH2—, or —N(R2)(CH2)n—”

A —C≡C— unit connects the two attachment points along a nearly linear axis. The triple bond fixes the axial separation while allowing the attached groups to rotate about that axis.

1.3Polar amide linker

What ifWhat if Y2 were an amide with its carbonyl carbon attached to the core and its nitrogen attached to the peripheral group?
Claim language“Y2 is —O—, —S—, —CH2—, or —N(R2)(CH2)n—”

The —C(=O)NH— bridge connects the two groups through a largely planar amide unit. Its carbonyl oxygen accepts hydrogen bonds, and its NH donates them.

1.4Saturated bicyclic ring fragment

What ifWhat if the aromatic ring fragment were replaced by a bicyclo[1.1.1]pentane unit attached through both bridgeheads?
Claim language“is phenyl, 5-9 membered heteroaryl”

The two bridgeheads provide fixed attachment points on opposite ends of the saturated cage. The three methylene bridges constrain the relative orientation of the attached groups.

1.6Acyclic ether terminal group

What ifWhat if B were a 2-methoxyethyl group attached through its first carbon?
Claim language“B is C1-C5 alkyl, aryl, heteroaryl, 5-9 membered heterocycloalkyl, or C3-C10-cycloalkyl”

The —CH2CH2OCH3 group places an ether oxygen two carbon atoms from the attachment point. The ether oxygen accepts hydrogen bonds from water, and rotation about the chain bonds lets the terminal methyl group sample several orientations.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Affinity matrix for research protein purification

An aminopyrimidine derivative with a terminal primary amine on B serves as the immobilized ligand. An activated agarose resin couples to the terminal amine through an amide bond, and ethanolamine caps residual activated groups. A cell extract passes through the packed resin, and a soluble form of the ligand competes for bound protein during elution. A capped resin without immobilized ligand measures background retention.

Component substitution

Alkyne bridge at the Y2 position

An ethynylene group occupies Y2 and connects the same two attachment sites through a rigid two-carbon bridge. A terminal alkynyl derivative of one ring couples to a halogenated derivative of the other ring under palladium catalysis. The isolated compound enters a MYC binding assay alongside the corresponding methylene-linked compound to measure the effect of the bridge substitution.

Bicyclic replacement for the phenyl ring

A bicyclo[1.1.1]pentane unit replaces a para-disubstituted phenyl ring, with the two attachments placed at the opposing bridgeheads. One bridgehead carries the connection to Y1, and the other carries the substituent corresponding to the para position. A bifunctional bicyclo[1.1.1]pentane building block supplies the two attachment sites, and the isolated analog enters paired solubility and MYC binding measurements with the phenyl reference.

Parameter or scale variation

Five to seven carbon linker series

A series of three analogs holds the aminopyrimidine core, B group, and linker nitrogen substituent fixed. Y2 is —N(R2)(CH2)n— with n set to 5, 6, or 7, giving a one-methylene increment between adjacent members. Each analog enters an eight-point, threefold dilution series spanning approximately 14 nM to 30 µM, with the same final solvent concentration in every well.

Combination with existing systems

MYC binding by surface plasmon resonance

A surface plasmon resonance instrument uses a flow cell bearing immobilized recombinant MYC and a reference flow cell with the same surface chemistry. Solutions of the aminopyrimidine or aminotriazine derivative pass through both cells at several concentrations, with matched solvent blanks between injections. The analysis subtracts the reference and blank responses and estimates the dissociation constant from the corrected equilibrium response as a function of concentration.

Automated or data-driven variant

Automated selection of matched analog pairs

Software enumerates aminopyrimidine and aminotriazine analogs from a stock list of ring fragments and prevalidated coupling templates. The software checks atom valence, removes duplicate structures, and groups compounds into pairs that differ at one specified attachment site. A liquid handler dispenses available compounds into assay plates in randomized order, with replicate wells and solvent controls. The analysis script joins each measurement to its molecular structure and ranks the pairs by the measured change in MYC binding.

Specific version of a part

One meta fluoro substituent

The phenyl ring attaches through carbon 1 and carries a single fluorine at carbon 3. The fluorine occupies the meta position relative to the attachment bond, and the other available ring positions carry hydrogen.

Carboxamide on a cyclohexyl group

The cyclohexyl group attaches through carbon 1 and bears a primary carboxamide, —C(=O)NH2, directly at carbon 4. The attachment bond and carboxamide occupy opposite faces of the ring in the trans isomer.

Methyl on a ring carbon

X1 is a ring carbon with R1 set to methyl. The carbon–carbon bond places the methyl group directly on the ring perimeter.

Cyclopropyl on an amide nitrogen

In a terminal amide bearing two R4 positions, one R4 is cyclopropyl and the other is hydrogen. The amide nitrogen bonds directly to one carbon of the three-membered ring and retains one NH hydrogen-bond donor.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2005/0215605 A1
Published
Sep 29, 2005
Filed
Mar 27, 2003
Document BUS 2020/0127207 A1
Published
Apr 23, 2020
Filed
Oct 12, 2016
Class
H01L 51/0055
Claim 1
Document A
Document B
1.1X1, X2, and X3 are each independently N or CR1, and wherein at least one of X1, X2, and X3 is N
A compound of the following Chemical Formula 1: wherein, in Chemical Formula 1, R1 and R2 are the same as or different from each other, and each independently a substituted or unsubstituted phenyl group; or a substituted or unsubstituted N-containing monocyclic heterocyclic group;
B · US 2020/0127207 A1 · claim 1
1.2Y1 is a bond, —O—, —S—, —CH2—, or —N(R2)(CH2)n—
In one embodiment of the present specification, L is a direct bond.
B · US 2020/0127207 A1 · ¶ 81
1.3Y2 is —O—, —S—, —CH2—, or —N(R2)(CH2)n—
1.4is phenyl, 5-9 membered heteroaryl
“Heteroaryl” refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group.
A · US 2005/0215605 A1 · ¶ 28
1.5wherein the phenyl and 5-9 membered heteroaryl are each optionally substituted with 1-3 R9 groups each independently selected from the group consisting of halogen, C1-C5 alkyl, C2-C5-alkenyl, C2-C5-alkynyl, C1-C5 haloalkyl, —(CH2)nOR3, and —NH2, with the proviso is not optionally substituted with 1-3 R′ groups each independently selected from the group consisting of halogen, C1-C5 alkyl, C2-C5-alkenyl, C2-C5-alkynyl, C1-C5 haloalkyl, —(CH2)nOR3, and —NH2
In a more preferred embodiment according to the invention, R1 is selected from the group consisting of an aryl or heteroaryl group optionally substituted with one or several substituents selected from the group consisting of aryl, heteroaryl, halogen, alkoxy, sulfanyl, straight or branched C1-C6-alkyl.
A · US 2005/0215605 A1 · ¶ 92
In the present specification, the term “substituted or unsubstituted” means being substituted with one or more substituents selected from the group consisting of hydrogen; deuterium; a halogen group; a nitrile group; an alkoxy group; a haloalkoxy group; an aryloxy group; an alkyl group; a haloalkyl group; a cycloalkyl group; an alkenyl group; a haloaryl group; an aralkyl group; an aralkenyl group; an alkylaryl group; a haloalkylaryl group; an aryl group; and a heterocyclic gr
B · US 2020/0127207 A1 · ¶ 29
1.6B is C1-C5 alkyl, aryl, heteroaryl, 5-9 membered heterocycloalkyl, or C3-C10-cycloalkyl
R3 is selected from the group consisting of substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted C2-C6-alkenyl, substituted or unsubstituted C2-C6-alkynyl, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl or substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted C1-C6-alkyl aryl, substituted or unsubstituted C1-C6-alkyl heteroaryl, substituted or unsubstituted C1-C3-alkyl cycloalkyl, substitute
A · US 2005/0215605 A1 · ¶ 103
Ar2 and Ar3 are the same as or different from each other, and each independently a substituted or unsubstituted aryl group; a substituted or unsubstituted silyl group; a substituted or unsubstituted alkyl group; a substituted or unsubstituted aralkyl group; or a substituted or unsubstituted heteroaryl group, or may bond to each other to form a substituted or unsubstituted ring,
B · US 2020/0127207 A1 · ¶ 77
1.7wherein the aryl, heteroaryl, 5-9 membered heterocycloalkyl, and C3-C10-cycloalkyl are each optionally substituted with 1-3 R8 groups each independently selected from the group consisting of —(CH2)nCN, —(CH2)nOH, —(CH2)nN(R4)2, —(CH2)nC(O)N(R4)2, —(CH2)nNR4C(O)R4, —(CH2)nNR4C(O)N(R4)2, —(CH2)nNR4 (C1-C5)alkylene(O)R44, —(CH2)nC(O)R4, —(CH2)nCO2R4, —(CH2)nOC(O)R4, —(CH2)nOC(O)OR4, —(CH2)nO(C1-C5-alkylene)N(R4)2, —(CH2)nSR4, —(CH2)nS(O)R4, —(CH2)nS(O)2R4, —(CH2)nN(R4)S(O)2R4, —(CH2)nS(O)2N(R4)2, halogen, C1-C5-alkyl, C2-C5-alkenyl, C2-C5-alkynyl, C1-C5-haloalkyl, aryl, alkylaryl, heteroaryl, 5-9 membered heterocycloalkyl, C3-C9-cycloalkyl, C1-C5-alkoxy, and C1-C5-haloalkoxy, and wherein said aryl and heteroaryl are each optionally substituted with 1 or 2 C1-C5-alkyl, and said 5-9 membered heterocycloalkyl is optionally substituted with 1 or 2 substituents each independently selected from C1-C5-alkyl and oxo
R2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C1-C5-alkyl carboxy, C1-C5-alkyl acyl, C1-C5-alkyl alkoxycarbonyl, C1-C5-alkyl aminocarbonyl, C1-C5-alkyl acyloxy, C1-C5-alkyl acylamino, C1-C5-alkyl ureido, C1-C5-alkyl amino, C1-C5-alkyl alkoxy, C1-C5-alkyl sulfanyl, C1-C5-alkyl sulfinyl, C1-C5-alkyl sulfonyl, C1-C5-alkyl sulfonylamino, C1-C5-alkyl sulfonyloxy, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cyclo
A · US 2005/0215605 A1 · claim 1
1.8R1 is hydrogen, halogen, or C1-C5 alkyl
R3 and R4 are the same as or different from each other, and each independently hydrogen; deuterium; a halogen group; a nitrile group; a substituted or unsubstituted alkyl group; a substituted or unsubstituted haloalkyl group; a substituted or unsubstituted alkoxy group; a substituted or unsubstituted haloalkoxy group; a substituted or unsubstituted alkylsilyl group; a substituted or unsubstituted arylsilyl group; a substituted or unsubstituted cyanoaryl group; a substituted o
B · US 2020/0127207 A1 · claim 1
1.9R2 and R3 are each independently hydrogen or C1-C5 alkyl
1.10R4 is hydrogen, halogen, aryl, heteroaryl, C1-C5 alkyl, C3-C6-cycloalkyl, or 3-6 membered heterocycloalkyl
R5, R6 and R7 are independently selected from the group consisting of H, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl C3-C8-heterocycloalkyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C1-C6-alkyl cycloalkyl, C1-C6-alkyl heterocycloalkyl, C2-C6-alkenyl aryl C2-C6-alkenyl heteroaryl, C2-C6-alkynyl aryl and C2-C6-alkynyl heteroaryl; or R6 and R7, or R5 and B—R6 together with the respective nitrogen atoms to which they are attached, optionally for
A · US 2005/0215605 A1 · claim 8
1.11wherein the aryl is unsubstituted or substituted with halogen, —OH, or —CN
1.12R4A is aryl, heteroaryl, C1-C5 alkyl, C3-C6-cycloalkyl, or 3-6 membered heterocycloalkyl each n is independently 0, 1, 2, 3, or 4.
R4 is selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl, and C2-C6-alkynyl; and n is an integer from 0 to 2; or R2 and G optionally form a C1-C8-cycloalkyl ring.
A · US 2005/0215605 A1 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
In the field of obstetrics, one of the most important problems is the management of preterm labor and premature birth as they represent a major cause of perinatal morbidity and mortality.
A · US 2005/0215605 A1 · ¶ 2
This present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.
A · US 2005/0215605 A1 · ¶ 1
Development of new materials for such an organic light emitting device has been continuously required.
B · US 2020/0127207 A1 · ¶ 4
Herein, the organic material layer is often formed in a multilayer structure formed with different materials in order to increase efficiency and stability of the organic light emitting device, and for example, may be formed with a hole injection layer, a hole transfer layer, a light emitting layer, an electron transfer layer, an electron injection layer and the like.
B · US 2020/0127207 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0356817 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356817/, SHA-256 d8b187e6be4c1c89bf84224b4bc71d98cdf45f0190881b25ae6432ecd05bd46d
First published
Permanent addresshttps://patent.fyi/US20260356817/
Content fingerprint (SHA-256)d8b187e6be4c1c89bf84224b4bc71d98cdf45f0190881b25ae6432ecd05bd46d
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi